Last reviewed · How we verify

Dapsone resistant leprosy — Treatment Landscape & Competitive Intelligence

Dapsone resistant leprosy (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Dapsone resistant leprosy, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Lamprene clofazimine Novartis Antimycobacterial ATP-binding cassette sub-family G member 2 1986-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Novartis · 1 drug in Dapsone resistant leprosy

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Dapsone resistant leprosy:

Cite this brief

Drug Landscape (2026). Dapsone resistant leprosy — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/dapsone-resistant-leprosy. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing